Daily Peptide News

Latest Peptide News & Research

Breaking research, regulatory updates, and industry developments in the world of peptide science. Updated daily.

Updated today at 6:00 PM UTC

STAT+: Pharmalittle: We're reading about employer coverage of obesity drugs, another Sanofi setback, and more

A growing number of employers are moving to drop coverage of GLP-1 receptor agonists for weight loss in the coming year, reflecting mounting cost pressures as adoption of these medications continues to rise. The trend signals a significant shift in how payers are approaching obesity pharmacotherapy, with potential downstream effects on patient access to drugs such as semaglutide and tirzepatide. This development carries broad implications for the market trajectory of GLP-1 based treatments and the compounding pharmacy sector that has served patients seeking lower-cost alternatives.

GLP-1SemaglutideTirzepatide

STAT NewsJune 11, 2026

4 min read

RegulatoryMedium

STAT+: The shortage of many medicines in the U.S. remains a 'systemic' problem, a new analysis finds

Persistent systemic drug shortages continue to affect compounding pharmacies that rely on access to active pharmaceutical ingredients and commercially available reference products. Providers prescribing peptide therapies sourced through compounding channels should be aware that supply chain instability may affect product availability and regulatory justification for compounding under shortage designations. Practices should maintain updated documentation of any shortage-based compounding rationale and communicate proactively with their compounding pharmacy partners.

STAT NewsJune 9, 2026

3 min read

RegulatoryCritical

Unproven Peptides Need More Regulation, AMA Delegates Say

Members of the American Medical Association House of Delegates passed a resolution at their annual meeting calling on the FDA to strengthen its regulatory oversight of unproven peptide therapies. The move signals growing institutional pressure on federal regulators to address the expanding market for peptides that lack robust clinical evidence and formal approval status. This development carries significant implications for compounding pharmacies and practitioners operating in the peptide therapy space.

MedPage TodayJune 9, 2026

4 min read

Clinical TrialsHigh

Drug Fights GLP-1 Muscle Loss; Unapproved Retatrutide Prescriptions; Protein Swap

A randomized phase II trial found that investigational apitegromab, a selective myostatin activation inhibitor, effectively preserved lean mass when combined with tirzepatide, addressing one of the most significant concerns associated with GLP-1 and GIP receptor agonist therapies. The findings suggest a potential combination strategy for mitigating muscle loss in patients undergoing weight management treatment with agents such as Zepbound or Ozempic. The report also highlights ongoing concerns around unapproved prescribing of retatrutide, an investigational triple agonist peptide therapy.

TirzepatideRetatrutideGLP-1GIP

MedPage TodayJune 9, 2026

5 min read

IndustryMedium

CDC Trust Falls Sharply; Watchdog Flags Medicaid Gaps; Drug Targets 'Ozempic Butt'

A Harvard School poll reveals that public trust in CDC health recommendations has dropped from 77 percent in spring 2025 to just 50 percent, reflecting a broader erosion of confidence in federal health institutions. The roundup also references emerging pharmaceutical interest in addressing body composition side effects associated with GLP-1 receptor agonist use, a growing concern among patients on semaglutide and similar therapies. These developments carry implications for patient adherence and the public perception of peptide-based weight loss treatments.

GLP-1Semaglutide

MedPage TodayJune 9, 2026

4 min read

IndustryHigh

Gilead and Merck's latest trial success and flop

A biotech news roundup highlights AstraZeneca's advancement of an oral GLP-1 pill candidate, signaling continued industry momentum toward next-generation formulations of glucagon-like peptide receptor agonists. The development of oral GLP-1 therapies represents a significant area of pharmaceutical competition with direct relevance to the peptide therapy landscape. If successful, such formulations could reshape patient access and compounding pharmacy dynamics for GLP-1 class treatments.

GLP-1

STAT NewsJune 9, 2026

4 min read

ResearchHigh

GLP-1s appear to protect against cancer. Researchers are trying to figure out how

Emerging research presented at major oncology conferences suggests that GLP-1 receptor agonists such as semaglutide and tirzepatide may offer protective effects against certain cancers beyond their established roles in weight loss and glycemic control. Scientists are investigating whether these peptide-based therapies act on brain and metabolic pathways independently of weight reduction to inhibit tumor progression. The findings represent a potentially significant expansion of the therapeutic applications of GLP-1 class peptides.

GLP-1SemaglutideTirzepatide

NPR HealthJune 9, 2026

5 min read

Clinical TrialsHigh

#ADA26: AstraZeneca GLP-1 pill cuts weight 10.5% after six months

AstraZeneca reported that its oral GLP-1 receptor agonist achieved a 10.5% reduction in body weight over six months in clinical data presented at ADA 2026, intensifying competition in the race for an approved obesity pill. The result positions AstraZeneca alongside Roche, Pfizer, and Structure Therapeutics as firms pursuing oral alternatives to injectable GLP-1 therapies. The data represents a significant development in the effort to expand patient access to GLP-1 based obesity treatments beyond injectable formulations.

GLP-1

Endpoints NewsJune 8, 2026

4 min read

Clinical TrialsHigh

GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials

Trial data presented at ADA 2026 demonstrated that a fixed-dose weekly combination of cagrilintide, a novel amylin analog, and semaglutide produced significant reductions in both blood glucose and body weight across multiple type 2 diabetes populations. The combination injectable, known as CagriSema, represents a promising advance in multi-mechanism peptide therapy for metabolic disease. These results reinforce the therapeutic potential of pairing GLP-1 receptor agonists with complementary peptide agents to achieve superior glycemic and weight outcomes.

SemaglutideCagrilintideCagriSemaGLP-1

MedPage TodayJune 8, 2026

4 min read

BreakthroughCritical

Large Study Links GLP-1s to Lower Risk of Multiple Cancers

A large propensity-matched cohort study found that patients using GLP-1 receptor agonists for obesity treatment had a 41% lower risk of developing obesity-related cancers compared to those managed with diet or exercise alone over a two-year period. The findings suggest that GLP-1 receptor agonists may confer oncological benefits beyond their established metabolic effects, adding meaningful weight to the broader therapeutic case for this class of agents. Researchers and clinicians are likely to view this data as a significant prompt for further investigation into GLP-1 mechanisms and cancer risk reduction.

GLP-1

MedPage TodayJune 8, 2026

5 min read

Clinical TrialsHigh

STAT+: AstraZeneca's GLP-1 pill shows promise in obesity, diabetes trials

Mid-stage clinical data from AstraZeneca's oral GLP-1 receptor agonist program showed encouraging results in both obesity and type 2 diabetes populations, though analysts note that its competitive positioning relative to other oral entrants remains unclear. The trials add to a growing body of evidence supporting the viability of non-injectable GLP-1 formulations for metabolic disease management. Questions around differentiation and long-term outcomes will be central to determining the candidate's commercial and clinical trajectory.

GLP-1

STAT NewsJune 8, 2026

5 min read

Clinical TrialsHigh

Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

Phase III trial data presented at ADA 2026 demonstrated that survodutide, a dual GLP-1 and glucagon receptor agonist, produced meaningful weight loss and reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease. However, tolerability emerged as a notable concern, with approximately one fifth of participants experiencing adverse events that warrant further evaluation. The findings highlight the ongoing challenge of balancing efficacy with safety profiles in next-generation receptor agonist therapies.

SurvodutideGLP-1

MedPage TodayJune 8, 2026

4 min read

IndustryHigh

STAT+: Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Eli Lilly released new safety and tolerability data for retatrutide, its next-generation triple-agonist obesity candidate targeting GLP-1, GIP, and glucagon receptors. The disclosure adds to a growing body of evidence supporting retatrutide as a potentially best-in-class agent in the competitive obesity drug landscape. Pfizer also contributed new obesity drug trial data, underscoring the intensifying race among major pharmaceutical players in this therapeutic area.

RetatrutideGLP-1GIP

STAT NewsJune 8, 2026

4 min read

IndustryHigh

#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot

Novo Nordisk has set a target of 2030 for the commercial launch of its triple-G agonist, a molecule designed to simultaneously activate GLP-1, GIP, and glucagon receptors for enhanced obesity treatment. Emerging data from the ADA 2026 conference indicate that this class of agents may surpass existing GLP-1 and dual-agonist therapies in terms of weight reduction efficacy. Eli Lilly currently leads the triple-G development race with retatrutide, but Novo Nordisk's entry signals a broadening competitive field.

GLP-1GIPRetatrutide

Endpoints NewsJune 8, 2026

4 min read

Clinical TrialsHigh

Monthly GLP-1 for Obesity Promising as More Manageable Alternative

An investigational ultra-long-acting GLP-1 receptor agonist demonstrated significant weight loss outcomes in individuals with overweight or obesity, with results sustained following a transition to once-monthly dosing. The findings, presented at a major endocrinology conference, suggest that extended-interval dosing schedules may improve patient adherence without sacrificing clinical efficacy. This development represents a meaningful step forward in the evolution of GLP-1 based obesity therapies beyond current weekly injection regimens.

GLP-1

MedPage TodayJune 8, 2026

4 min read

Clinical TrialsCritical

Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide

Phase III TRANSCEND-T2D-1 trial data presented at ADA 2026 demonstrates that once-weekly retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, enabled up to 40% of type 2 diabetes patients to achieve normal HbA1c levels as monotherapy. The results position retatrutide as a potentially best-in-class investigational agent among the next generation of incretin-based therapies. This landmark trial outcome adds significant momentum to the competitive landscape of multi-receptor agonist peptides in metabolic disease management.

RetatrutideGLP-1GIP

MedPage TodayJune 7, 2026

5 min read

ResearchMedium

Add This To Your Meals To Support GLP-1, Blood Sugar & Gut Health

Emerging nutritional research highlights specific dietary ingredients that may naturally support endogenous GLP-1 secretion, blood sugar regulation, and gut microbiome health. The findings are relevant to the broader conversation around metabolic optimization and the role of lifestyle factors in complementing GLP-1 receptor agonist therapies. Understanding dietary modulators of GLP-1 activity offers context for patients and clinicians navigating combination approaches to metabolic health.

GLP-1

MindBodyGreenJune 6, 2026

3 min read

Clinical TrialsHigh

Add-On Orforglipron: Good News for Type 2 Diabetes and Inadequate Glycemic Control

The international ACHIEVE-5 trial demonstrated that once-daily orforglipron, an oral non-peptide GLP-1 receptor agonist, improved glycemic outcomes in adults with type 2 diabetes already receiving background insulin glargine therapy. The findings support orforglipron as a viable add-on option for patients with inadequate glycemic control, broadening the therapeutic utility of GLP-1 receptor agonism beyond injectable formulations. This trial adds to a growing body of evidence supporting oral incretin-based agents as a meaningful advancement in diabetes care.

OrforglipronGLP-1

MedPage TodayJune 7, 2026

4 min read

Clinical TrialsHigh

STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly presented updated safety and tolerability data on retatrutide, its investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, at the American Diabetes Association annual meeting. The data adds to the growing body of evidence supporting retatrutide as a next-generation advance beyond current dual-agonist therapies. This presentation marks a significant milestone in the competitive obesity and metabolic disease treatment landscape.

RetatrutideGLP-1GIP

STAT NewsJune 6, 2026

4 min read

Clinical TrialsHigh

#ADA26: Pfizer monthly shot shows effect on obesity, diabetes

Pfizer presented clinical data at ADA 2026 demonstrating that berobenatide, a long-acting monthly GLP-1 receptor agonist formerly known as PF-08653944, shows meaningful efficacy in patients managing both obesity and type 2 diabetes. The asset, which became central to Pfizer's portfolio following its acquisition of Metsera, represents a potential shift toward less frequent dosing schedules in the GLP-1 therapeutic space. These results underscore the continued acceleration of next-generation incretin-based therapies targeting metabolic disease.

GLP-1BerobenatidePF-08653944

Endpoints NewsJune 6, 2026

4 min read

ResearchMedium

The Lifestyle Habits That Could Extend Your Life After Cancer

A recent report highlights newly identified mechanisms through which GLP-1 receptor agonist drugs exert effects beyond glycemic control and weight loss, with implications for oncology and survivorship care. Scientists are uncovering additional biological pathways activated by GLP-1 drugs that may contribute to improved long-term health outcomes in cancer survivors. These findings add to the expanding body of evidence supporting pleiotropic benefits of GLP-1 based therapies.

GLP-1

MindBodyGreenJune 5, 2026

3 min read

IndustryMedium

STAT+: Newer GLP-1s, pushback on research cuts, and a protest

Coverage from the American Diabetes Association annual conference highlights the emergence of next-generation GLP-1 receptor agonists alongside growing concern from researchers over potential funding reductions affecting metabolic disease study. The report captures the scientific and political tensions shaping the near-term landscape of incretin-based therapeutics. Developments presented at the conference signal continued momentum in GLP-1 drug innovation despite institutional headwinds.

GLP-1

STAT NewsJune 5, 2026

3 min read

Clinical TrialsHigh

#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetes

Roche has reported promising Phase 2 trial results for a daily incretin-based injection in type 1 diabetes, a population historically considered outside the therapeutic scope of GLP-1 based treatments. The findings, presented at the American Diabetes Association annual conference, suggest incretin receptor targeting may have broader applicability than previously understood. This mid-stage data represents a notable expansion of the incretin drug class into autoimmune-driven metabolic disease.

GLP-1

Endpoints NewsJune 5, 2026

4 min read

ResearchHigh

New Study Explains Why Some People Taking GLP-1s Notice Fewer Cravings

A new study has shed light on an additional mechanism by which GLP-1 receptor agonists reduce cravings beyond their well-known appetite suppression effects. Researchers identified neurological and behavioral pathways that may explain differential patient responses to these medications. The findings add to the growing body of evidence supporting the broader systemic effects of GLP-1 based therapies.

GLP-1SemaglutideTirzepatide

MindBodyGreenJune 5, 2026

4 min read

Clinical TrialsCritical

Accumulating Evidence Lifts GLP-1s to Clinical Trial for Breast Cancer Prevention

A large-scale observational study of more than 30,000 women undergoing breast imaging has found a significantly lower incidence of breast cancer among those with a history of GLP-1 agonist use, prompting advancement to formal clinical trial investigation. The findings, presented at ASCO 2026, add to a growing body of evidence suggesting oncologic benefits beyond metabolic indications for this class of receptor agonists. Researchers and clinicians are now closely watching whether prospective trial data will support a new preventive application for GLP-1 therapies.

GLP-1SemaglutideTirzepatide

MedPage TodayJune 4, 2026

5 min read

IndustryCritical

Parabilis Medicines charts $413M IPO to back peptide pipeline

Parabilis Medicines, the peptide-focused biotech helmed by former Johnson and Johnson R&D chief Mathai Mammen, is pursuing a Nasdaq IPO targeting over $413 million to advance its peptide drug pipeline. The offering represents one of the more significant public market entries for a dedicated peptide therapeutics company in recent memory. If successful, the listing would provide substantial capital to accelerate the development of novel peptide based candidates across multiple therapeutic areas.

Endpoints NewsJune 4, 2026

4 min read

IndustryHigh

What it will take for more employer GLP-1 coverage

Eli Lilly has announced that its weight loss medications are now covered for millions of Americans following inclusion by all three major pharmacy benefit managers. The expansion of GLP-1 coverage through employer-sponsored plans remains a critical inflection point for patient access and market growth. Broader employer adoption could significantly accelerate the use of GLP-1 receptor agonists across the U.S. workforce.

GLP-1Tirzepatide

Endpoints NewsJune 3, 2026

4 min read

ResearchHigh

STAT+: Pharmalittle: We're reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more

A new study indicates that sustained use of GLP-1 weight loss medications for at least three years may prevent thousands of knee replacement surgeries annually. The findings add to a growing body of evidence supporting the musculoskeletal benefits of GLP-1 receptor agonists beyond metabolic and cardiovascular outcomes. This research reinforces the broader therapeutic potential of this drug class and may influence future coverage and prescribing decisions.

GLP-1SemaglutideTirzepatide

STAT NewsJune 3, 2026

3 min read

IndustryHigh

Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfront

Eli Lilly has entered a licensing agreement with South Korean biopharmaceutical company Hanmi, paying $75 million upfront to secure rights to a GLP-2 receptor agonist asset. The deal signals a strategic expansion by Lilly beyond its blockbuster GLP-1 franchise into gut-focused peptide therapeutics. GLP-2 agonists have shown promise in intestinal repair and metabolic applications, representing a notable frontier in peptide-based drug development.

GLP-1GLP-2

Endpoints NewsJune 1, 2026

4 min read

RegulatoryCritical

STAT+: Medicare still won't say how much covering obesity drugs will cost

As Medicare prepares to offer Wegovy and Zepbound to eligible seniors at a $50 monthly copay beginning July 2026, the agency continues to withhold any public cost estimates for the program. The absence of fiscal projections has drawn criticism from budget watchdogs and lawmakers who argue taxpayers deserve transparency before the rollout begins. The situation underscores broader tensions surrounding large-scale public coverage of high-cost GLP-1 receptor agonist therapies.

GLP-1SemaglutideTirzepatide

STAT NewsJune 1, 2026

5 min read

ResearchHigh

The hidden history of BPC-157, a favorite MAHA peptide

STAT News examines the decades-long scientific and political journey of BPC-157, a regenerative peptide originally nicknamed "substance God help me" by its primary researcher Predrag Sikiric. The compound has gained renewed attention amid favorable commentary from health policy figures including RFK Jr., who has expressed openness to peptide-based therapeutic approaches. The article addresses longstanding skepticism from mainstream researchers while acknowledging the growing popular and political momentum behind BPC-157.

BPC-157

STAT NewsJune 1, 2026

6 min read

RegulatoryHigh

STAT+: Medicare's mum on GLP-1s, and Massachusetts sues United

Medicare has declined to disclose cost projections related to its newly announced coverage of GLP-1 obesity medications for seniors at a $50 monthly cap. The lack of transparency raises significant questions about federal budget exposure as the program is set to launch in July 2026. Policy analysts and advocates continue to press the agency for estimates that could shape future drug pricing and coverage decisions.

GLP-1SemaglutideTirzepatide

STAT NewsJune 1, 2026

4 min read

Clinical TrialsHigh

Opinion: I'm a weight-loss doctor. Here's why I worry about GLP-1 'microdoses'

A weight-loss physician raises clinical concerns about the growing trend of microdosing GLP-1 receptor agonists for cosmetic weight loss, citing a lack of long-term evidence supporting the practice. The opinion piece highlights uncertainty around the safety and efficacy profiles of sub-therapeutic GLP-1 dosing outside established clinical protocols. The perspective adds to ongoing debate surrounding off-label and compounded GLP-1 use as demand for these therapies continues to expand.

GLP-1SemaglutideTirzepatide

STAT NewsMay 29, 2026

4 min read

IndustryMedium

For wearables, it's a GLP-1 world

The wearable technology sector is increasingly intersecting with GLP-1 receptor agonist therapy, as companies such as Signos pursue funding to develop monitoring solutions tailored to patients using these peptide-based treatments. A recent $20 million raise by Signos highlights growing investor confidence in the convergence of digital health tools and incretin therapy management. This trend reflects the broader influence GLP-1 peptide therapies are having across adjacent healthcare and technology industries.

GLP-1

Endpoints NewsMay 28, 2026

3 min read

IndustryHigh

Lilly obesity meds Foundayo and Zepbound to gain CVS coverage

Eli Lilly's obesity medications Foundayo and Zepbound are set to gain inclusion in CVS Caremark formularies, marking a significant expansion in commercial insurance coverage for GLP-1 and GIP receptor agonist therapies. The move is expected to substantially boost patient access and sales volume in the highly competitive obesity drug market. This development underscores the growing formulary acceptance of incretin-based peptide therapies as standard-of-care treatments for obesity.

TirzepatideGLP-1GIP

Endpoints NewsMay 28, 2026

4 min read

IndustryHigh

STAT+: Five biotech news updates to stay on top of today

Eli Lilly continues to deploy significant capital generated from its GLP-1 portfolio, signaling sustained confidence in the receptor agonist drug class as a long-term revenue driver. The development reflects broader industry momentum around GLP-1 based therapies and their expanding commercial footprint. Strategic reinvestment at this scale may have downstream implications for research, pipeline development, and market competition in the peptide therapeutics space.

GLP-1Tirzepatide

STAT NewsMay 26, 2026

4 min read

RegulatoryHigh

AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel

The European Medicines Agency issued a positive opinion for Novo Nordisk's oral Wegovy formulation, marking a significant regulatory milestone for GLP-1 receptor agonist therapy in a new delivery format. The EU approval of an oral semaglutide weight management option expands patient access options beyond injectable formulations currently dominant in the market. This development signals continued momentum for GLP-1 based therapies in major global markets even as regulatory bodies occasionally diverge in their assessments.

SemaglutideGLP-1

Endpoints NewsMay 22, 2026

4 min read

Clinical TrialsCritical

Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy

Eli Lilly has released clinical trial results for retatrutide, a next-generation obesity treatment demonstrating an average weight loss of 70 pounds over 80 weeks, surpassing the efficacy of existing GLP-1 receptor agonists including tirzepatide and semaglutide. The trial results position retatrutide as a potential new benchmark in peptide-based obesity pharmacotherapy. This development signals a continued acceleration in the GLP-1 and multi-incretin peptide therapeutic space with significant implications for both clinical practice and the compounding pharmacy market.

RetatrutideTirzepatideSemaglutideGLP-1GIP

NPR HealthMay 22, 2026

4 min read

IndustryHigh

Driven by GLP-1s, pharma's relationship with consumers is starting to change

The widespread consumer demand for GLP-1 receptor agonists has accelerated a fundamental shift in how pharmaceutical companies engage directly with patients. Direct-to-consumer channels have expanded significantly as patients demonstrate willingness to pay out of pocket for weight loss therapies, compelling manufacturers to rethink traditional distribution and communication models. This evolution signals a broader transformation in patient-pharma dynamics that is likely to shape how peptide-based therapeutics are marketed and accessed going forward.

GLP-1SemaglutideTirzepatide

Endpoints NewsMay 20, 2026

4 min read

RegulatoryCritical

STAT+: Maryland state affordability board places a price cap on Ozempic

Maryland's prescription drug affordability board has set a price cap on Ozempic, marking a significant move among the nine states pursuing similar affordability measures for high-cost medications. The decision represents a direct state-level intervention in the pricing of semaglutide, one of the most widely prescribed GLP-1 receptor agonists in the United States. This action could serve as a precedent for other states seeking to regulate the cost of GLP-1 therapies and related peptide-based treatments.

SemaglutideGLP-1

STAT NewsMay 18, 2026

4 min read

IndustryHigh

STAT+: Hims takes a $33 million hit from GLP-1 'pivot'

Telehealth company Hims and Hers reported a 33 million dollar financial loss attributable to its strategic shift away from compounded GLP-1 offerings following regulatory pressure on compounding pharmacies. The earnings report underscores the significant commercial consequences facing digital health platforms that had built revenue streams around compounded semaglutide and tirzepatide products. The development reflects the broader industry disruption triggered by FDA actions on compounded GLP-1 receptor agonists.

SemaglutideTirzepatideGLP-1

STAT NewsMay 12, 2026

4 min read

Clinical TrialsHigh

Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options

New clinical trial data from Eli Lilly suggests that reduced doses of tirzepatide, marketed as Zepbound, may offer a safe and effective strategy for long-term weight loss maintenance at potentially lower cost. The findings highlight the flexibility of GLP-1/GIP receptor agonist dosing protocols in managing obesity beyond the initial treatment phase. This development could expand patient access and inform future prescribing guidelines for tirzepatide-based therapies.

TirzepatideGLP-1GIP

Endpoints NewsMay 12, 2026

4 min read

IndustryHigh

Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

Novo Nordisk's Wegovy, which received approval in August 2025 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), is reshaping the fatty liver disease market alongside existing therapies. The competitive landscape is demonstrating that GLP-1 receptor agonists can coexist with other approved MASH treatments, with both categories drawing significant commercial interest. This development underscores the expanding therapeutic footprint of GLP-1 based agents beyond weight loss and diabetes management.

SemaglutideGLP-1

Endpoints NewsMay 11, 2026

4 min read

Clinical TrialsCritical

European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy

European regulatory authorities have approved Fractyl Health to proceed with clinical testing of a GLP-1 gene therapy designed to provide a single-administration alternative to chronic GLP-1 receptor agonist injections. The clearance positions Fractyl Health as a potential pioneer in translating GLP-1 biology from peptide-based therapies into durable genetic medicine. This milestone highlights a broader industry shift toward long-acting and one-time interventions that could significantly disrupt the current peptide injection market.

GLP-1

Endpoints NewsMay 11, 2026

4 min read

IndustryHigh

Amazon adds Ozempic pill to same-day prescription drug kiosks

Amazon Pharmacy has expanded its prescription drug kiosk network to include the oral formulation of Ozempic, following the addition of oral Wegovy in February. The move signals growing retail accessibility for GLP-1 receptor agonist medications, positioning same-day dispensing as a competitive channel for semaglutide-based therapies. This development reflects the accelerating consumer demand and distribution innovation surrounding GLP-1 treatments.

SemaglutideGLP-1

Endpoints NewsMay 7, 2026

3 min read

IndustryMedium

Entrada stock falls on Duchenne data; Wegovy expands access

Wegovy has secured expanded patient access, marking a continued broadening of semaglutide availability across healthcare markets. The news accompanies a broader industry update covering multiple biotech developments. Expanded access to GLP-1 therapies such as Wegovy remains a closely watched trend for both payers and prescribers.

SemaglutideGLP-1

Endpoints NewsMay 7, 2026

4 min read

IndustryHigh

STAT+: Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price

Novo Nordisk received a market boost following updated data on its oral semaglutide formulation, branded as the Wegovy pill, which showed results sufficient to reassure investors amid growing competition in the GLP-1 space. The earnings lift signals continued commercial momentum for oral weight loss therapies as the sector faces increasing pricing and access pressures. Analysts are closely watching how oral GLP-1 formulations reshape the competitive landscape previously dominated by injectable options.

A new Medicare option for weight loss drugs is coming: Here's what to know

Medicare is preparing to offer millions of eligible beneficiaries access to discounted GLP-1 receptor agonist medications for weight loss through a new cost-sharing program, representing a significant expansion of federal coverage for peptide-based obesity therapies. The policy development marks a pivotal shift in how the United States government approaches pharmacological obesity treatment at scale. Healthcare advocates note that improved affordability could substantially increase patient uptake of GLP-1 drugs among older Americans.

GLP-1SemaglutideTirzepatide

NPR HealthMay 6, 2026

4 min read

IndustryHigh

Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure

Novo Nordisk reported that one million obesity patients are now taking its oral semaglutide Wegovy pill, generating 2.3 billion Danish kroner in early sales despite the market entry of Eli Lilly's competing oral GLP-1 product Foundayo. The Q1 results highlight intensifying commercial rivalry in the oral GLP-1 receptor agonist segment, with pricing and reimbursement dynamics emerging as central battlegrounds. The milestone underscores rapid patient adoption of non-injectable peptide therapies for obesity management.

SemaglutideGLP-1Tirzepatide

Endpoints NewsMay 6, 2026

5 min read

Clinical TrialsHigh

Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M

A newly reported blood test may offer clinicians a predictive tool for identifying patients most likely to respond to Wegovy (semaglutide), a development that could meaningfully improve prescribing decisions in obesity medicine. The finding represents a step toward more personalized GLP-1 receptor agonist therapy and addresses one of the persistent clinical challenges of variable patient response. This signal, embedded within a broader industry roundup, underscores growing momentum around biomarker-guided approaches to peptide-based obesity treatment.

SemaglutideGLP-1

Endpoints NewsMay 5, 2026

5 min read